Understanding the NSAID related risk of vascular events

BMJ. 2006 Apr 15;332(7546):895-8. doi: 10.1136/bmj.332.7546.895.

Authors

Harald E Vonkeman¹, Jacobus R B J Brouwers, Mart A F J van de Laar

Affiliation

¹ Department of Rheumatology and Clinical Immunology, Medisch Spectrum Twente Hospital and University of Twente, Enschede, Netherlands. H.Vonkeman@ziekenhuis-mst.nl

No abstract available

Publication types

Review

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
Cardiovascular Diseases / chemically induced*
Cyclooxygenase 1 / physiology
Cyclooxygenase 2 / physiology
Cyclooxygenase 2 Inhibitors / adverse effects*
Humans
Risk Factors

Substances

Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase 2 Inhibitors
Cyclooxygenase 1
Cyclooxygenase 2